Motor neuron disease (MND) Research

Our Research Portfolio

Since our formation in 2017, we have invested over £11 million in a targeted portfolio of MND research to expedite the development of new treatments.

We support innovative projects across all three of the strategic priorities in our research strategy.

Our investments cover lab-based “pre-clinical” research, through to clinical studies to test the most promising treatments in people living with MND.

Strategic Priorities

Announcing a £1.27 Million Investment in Our 2023 Advancing Treatment Awards

Sign up to our email newsletters